-
-
-
-
-
-
-
Wells Fargo on Neurocrine Bio. (NBIX): 'Defending NBIX, We Would Be Buyers Here'
-
-
-
-
-
-
-
Neurocrine Bio. (NBIX) PT Raised to $200 at Truist Securities
-
-
-
-
-
-
-
Neurocrine presents tardive dyskinesia treatment data at conference
-
-
-
-
-
-
-
Neurocrine Bio. (NBIX) PT Raised to $155 at Truist Securities
-
-
-
-
-
-
-
Neurocrine reports sustained dose reductions with CRENESSITY in CAH patients
-
-
-
-
-
-
-
Neurocrine Bio. (NBIX) PT Raised to $220 at Oppenheimer on SLNO deal
-
-
-
-
-
-
-
Wolfe Research Starts Neurocrine Bio. (NBIX) at Outperform
-
461,063 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

